ICICI Securities Limited
Slump in price of key APIs has exerted pressure on growth in Akums CDMO segment for the past several quarters, we believe this trend is now starting to reverse as API prices are now stabilizing.
Akums Drugs & Pharma has lost -25.36% in the last 1 Year
More from Akums Drugs & Pharmaceuticals Ltd.
Recommended